These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 21077681

  • 1. Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids.
    Zhu Y, Wu G, Zhu X, Ma Y, Zhao X, Li Y, Yuan Y, Yang J, Yu S, Shao F, Lei M.
    J Med Chem; 2010 Dec 23; 53(24):8619-26. PubMed ID: 21077681
    [Abstract] [Full Text] [Related]

  • 2. Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids.
    Zhu Y, Zhu X, Wu G, Ma Y, Li Y, Zhao X, Yuan Y, Yang J, Yu S, Shao F, Li R, Ke Y, Lu A, Liu Z, Zhang L.
    J Med Chem; 2010 Mar 11; 53(5):1990-9. PubMed ID: 20158184
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates.
    Zhu Y, Zhao X, Zhu X, Wu G, Li Y, Ma Y, Yuan Y, Yang J, Hu Y, Ai L, Gao Q.
    J Med Chem; 2009 Jul 23; 52(14):4192-9. PubMed ID: 19537716
    [Abstract] [Full Text] [Related]

  • 4. Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.
    Milo LJ, Lai JH, Wu W, Liu Y, Maw H, Li Y, Jin Z, Shu Y, Poplawski SE, Wu Y, Sanford DG, Sudmeier JL, Bachovchin WW.
    J Med Chem; 2011 Jul 14; 54(13):4365-77. PubMed ID: 21634429
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.
    Zhu Y, Yao S, Xu B, Ge Z, Cui J, Cheng T, Li R.
    Bioorg Med Chem; 2009 Oct 01; 17(19):6851-61. PubMed ID: 19747832
    [Abstract] [Full Text] [Related]

  • 6. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 7. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
    Dorsey BD, Iqbal M, Chatterjee S, Menta E, Bernardini R, Bernareggi A, Cassarà PG, D'Arasmo G, Ferretti E, De Munari S, Oliva A, Pezzoni G, Allievi C, Strepponi I, Ruggeri B, Ator MA, Williams M, Mallamo JP.
    J Med Chem; 2008 Feb 28; 51(4):1068-72. PubMed ID: 18247547
    [Abstract] [Full Text] [Related]

  • 8. Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.
    Watanabe T, Momose I, Abe M, Abe H, Sawa R, Umezawa Y, Ikeda D, Takahashi Y, Akamatsu Y.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2343-5. PubMed ID: 19307118
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J, Lei M, Wu W, Feng H, Wang J, Chen S, Zhu Y, Hu S, Liu Z, Jiang C.
    Bioorg Med Chem Lett; 2016 Apr 15; 26(8):1958-62. PubMed ID: 26965867
    [Abstract] [Full Text] [Related]

  • 10. Identification of a potent and rapidly reversible inhibitor of the 20S-proteasome.
    Purandare AV, Wan H, Laing N, Benbatoul K, Vaccaro W, Poss MA.
    Bioorg Med Chem Lett; 2004 Sep 20; 14(18):4701-4. PubMed ID: 15324891
    [Abstract] [Full Text] [Related]

  • 11. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ.
    J Clin Oncol; 2004 Jun 01; 22(11):2108-21. PubMed ID: 15169797
    [Abstract] [Full Text] [Related]

  • 12. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
    Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM.
    J Clin Oncol; 2005 Sep 01; 23(25):6107-16. PubMed ID: 16135477
    [Abstract] [Full Text] [Related]

  • 13. Structure-activity relationship of boronic acid derivatives of tyropeptin: proteasome inhibitors.
    Watanabe T, Abe H, Momose I, Takahashi Y, Ikeda D, Akamatsu Y.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5839-42. PubMed ID: 20727746
    [Abstract] [Full Text] [Related]

  • 14. Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.
    Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS.
    Drug Metab Dispos; 2006 Apr 01; 34(4):702-8. PubMed ID: 16443666
    [Abstract] [Full Text] [Related]

  • 15. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Fujita T, Doihara H, Washio K, Ino H, Murakami M, Naito M, Shimizu N.
    Anticancer Drugs; 2007 Jul 01; 18(6):677-86. PubMed ID: 17762396
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
    Lei M, Feng H, Bai E, Zhou H, Wang J, Shi J, Wang X, Hu S, Liu Z, Zhu Y.
    Bioorg Med Chem; 2018 Aug 07; 26(14):3975-3981. PubMed ID: 29934218
    [Abstract] [Full Text] [Related]

  • 17. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP, Bay JO, Blay JY, Rixe O.
    Bull Cancer; 2005 Nov 07; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [Abstract] [Full Text] [Related]

  • 18. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.
    Marx C, Yau C, Banwait S, Zhou Y, Scott GK, Hann B, Park JW, Benz CC.
    Mol Pharmacol; 2007 Jun 07; 71(6):1525-34. PubMed ID: 17392524
    [Abstract] [Full Text] [Related]

  • 19. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K, Troiano V, Ettari R, Pinto A, Micale N, Di Giovanni C, Cerchia C, Schirmeister T, Novellino E, Lavecchia A, Zappalà M, Grasso S.
    ChemMedChem; 2014 Aug 07; 9(8):1801-16. PubMed ID: 24891205
    [Abstract] [Full Text] [Related]

  • 20. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L.
    Clin Cancer Res; 2007 Oct 01; 13(19):5942-51. PubMed ID: 17908991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.